沉默信息调节蛋白4与糖尿病肾病的相关性
|
摘要
糖尿病肾病是糖尿病最常见也是最严重的并发症之一,全世界范围内其发病率逐渐上升。糖尿病肾病是遗传及多因素作用的结果,目前已知足细胞凋亡、胰岛素抵抗、脂肪酸氧化、氧化应激、炎症反应均是促进糖尿病肾病发生发展的危险因素。沉默信息调节蛋白4 (SIRT4)是一种依赖烟酰胺腺嘌呤二核苷酸的酶类,它同时具有ADP-核糖转移酶活性、去乙酰化酶活性、脂酰胺酶活性,可广泛参与到上述生物过程中。本文通过探究SIRT4与糖尿病肾病发病危险因素间的相互作用,推测SIRT4与糖尿病肾病的相关性。
The prevalence of diabetic nephropathy,a common and serious complication of diabetes,has been increasing worldwide.Diabetic nephropathy is the result of genetic and multifactorial effects. It is known that podocyte apoptosis,insulin resistance,fatty acid oxidation,oxidative stress,and an inflammatory state are risk factors for the development of diabetic nephropathy. Silencing regulatory protein 4(SIRT4) is a nicotinamide adenine dinucleotide-dependent protein deacetylase that has both ADP-ribosyltransferase activity and deacetylase activity and is widely involved in the above-mentioned biological processes. This article explores the possible association between SIRT4 and diabetic nephropathy by exploring the interaction between SIRT4 and the risk factors for diabetic nephropathy.
The prevalence of diabetic nephropathy,a common and serious complication of diabetes,has been increasing worldwide.Diabetic nephropathy is the result of genetic and multifactorial effects. It is known that podocyte apoptosis,insulin resistance,fatty acid oxidation,oxidative stress,and an inflammatory state are risk factors for the development of diabetic nephropathy. Silencing regulatory protein 4(SIRT4) is a nicotinamide adenine dinucleotide-dependent protein deacetylase that has both ADP-ribosyltransferase activity and deacetylase activity and is widely involved in the above-mentioned biological processes. This article explores the possible association between SIRT4 and diabetic nephropathy by exploring the interaction between SIRT4 and the risk factors for diabetic nephropathy.
引文
[1]MATSUSHIMA S,SADOSHIMA J.The role of sirtuins in cardiac disease[J].Am J Physiol Heart Circ Physiol,2015,309(9):H1375-H1389.DOI:10.1152/ajpheart.0053.2015.
[2]LINDBLOM R,HIGGINS G,COUGHLAN M,et al.Targeting mitochondria and reactive oxygen species-driven pathogenesis in diabetic nephropathy[J].Rev Diabet Stud,2015,12(1/2):134-156.DOI:10.1900/RDS.2015.12.134.
[3]KARALLIEDDE J,GNUDI L.Diabetes mellitus,a complex and heterogeneous disease,and the role of insulin resistance as a determinant of diabetic kidney disease[J].Nephrol Dial Transplant,2016,31(2):206-213.DOI:10.1093/ndt/gfu405.
[4]邬明辉,杨晓丽,韩秋霞,等.糖尿病肾病研究进展[J].中华肾病研究电子杂志,2018,7(2):86-90.DOI:10.3877/cma.j.issn.2095-3216.2018.02.008.
[5]SHI JX,WANG QJ,LI H,et al.SIRT4 overexpression protects against diabetic nephropathy by inhibiting podocyte apoptosis[J].Exp Ther Med,2017,13(1):342-348.DOI:10.3892/etm.2016.3938.
[6]HUYNH FK,HUX,LIN Z,et al.Loss of sirtuin 4 leads to elevated glucose-and leucine-stimulated insulin levels and accelerated age-induced insulin resistance in multiple murine genetic backgrounds[J].J Inherit Metab Dis,2018,41(1):59-72.DOI:10.1007/s10545-017-0069-8.
[7]STANLEY CA.Regulation of glutamate metabolism and insulin secretion by glutamate dehydrogenase in hypoglycemic children[J].Am J Clin Nutr,2009,90(3):862S-866S.DOI:10.3945/ajcn.2009.27462AA.
[8]AHUJA N,SCHWER B,CAROBBIO S,et al.Regulation of insulin secretion by SIRT4,a mitochondrial ADP-ribosyltransferase[J].J Biol Chem,2007,282(46):33583-33592.
[9]HAIGIS MC,MOSTOSLAVSKY R,HAIGIS KM,et al.SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells[J].Cell,2006,126(5):941-954.DOI:10.1016/j.cell.2006.06.057.
[10]LIU H,LIU R,XIONG Y,et al.Leucine facilitates the insulin-stimulated glucose uptake and insulin signaling in skeletal muscle cells:involving mTORC1 and mTORC2[J].Amino Acids,2014,46(8):1971-1979.DOI:10.1007/s00726-014-1752-9.
[11]ANDESON KA,HUYNH FK,FISHEI-WELLMAN K,et al.SIRT4is a lysine deacylase that controls leucine metabolism and insulin secretion[J].Cell Metab,2017,25(4):838-855.DOI:10.1016/j.cmet.2017.03.003.
[12]ZAGANJOR E,VYAS S,HAIGIS MC.SIRT4 is a regulator of insulin secretion[J].Cell Chem Biol,2017,24(6):656-658.DOI:10.1016/j.chembiol.2017.06.002.
[13]CHEN C,MATALE,FINN RD,et al.Representative proteomes:a stable,scalable and unbiased proteome set for sequence analysis and functional annotation[J].PLoS One,2011,6(4):e18910.DOI:10.1371/journal.pone.0018910.
[14]CHOUBEY SK,PRABHU D,MACHAIPPAN M,et al.Molecular modeling,dynamics studies and density functional theory approaches to identify potential inhibitors of SIRT4 protein from Homo sapiens:a novel target for the treatment of type 2 diabetes[J].J Biomol Struct Dyn,2017,35(15):3316-3329.DOI:10.1080/07391102.2016.1254117.
[15]LAURENT G,GERMAN NJ,SAHA AK,et al.SIRT4 coordinates the balance between lipid synthesis and catabolism by repressing malonyl CoA decarboxylase[J].Mol Cell,2013,50(5):686-698.DOI:10.1016/j.molcel.2013.05.012.
[16]LAURENT G,DE BOER VC,FINLY LW,et al.SIRT4 represses peroxisome proliferator-activated receptorαactivity to suppress hepatic fat oxidation[J].Mol Cell Biol,2013,33(22):4552-4561.DOI:10.1128/MCB.00087-13.
[17]LUO YX,TANG X,AN XZ,et al.SIRT4 accelerates AngⅡ-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity[J].Eur Heart J,2017,38(18):1389-1398.DOI:10.1093/eurheartj/ehw138.
[18]LANG A,ANAND R,ALTINOLUK-HANBUCHEN S,et al.SIRT4interacts with OPA1 and regulates mitochondrial quality control and mitophagy[J].Aging(Albany NY),2017,9(10):2163-2189.DOI:10.18632/aging.101307.
[19]TAO Y,HUANG C,HUANG Y,et al.SIRT4 suppresses inflammatory responses in human umbilical vein endothelial cells[J].Cardiovasc Toxicol,2015,5(3):217-223.DOI:10.1007/s12012-014-9287-6.
[20]TAO J,ZHANG J,LING Y,et al.Mitochondrial sirtuin 4 resolves immune tolerance in monocytes by rebalancing glycolysis and glucose oxidation homeostasis[J].Front Immunol,2018,9:419.DOI:10.3389/fimmu.2018.00419.
[21]KUME S,KOYA D,UZU T,et al.Role of nutrient-sensing signals in the pathogenesis of diabetic nephropathy[J].Biomed Res Int,2014,2014:315494.DOI:10.1155/2014/315494.
[22]吴贤,杨瑜.血清SIRT4水平与肥胖程度及血清IGF-1的相关性研究[J].江西医药,2018,53(1):38-40.DOI:10.3969/j.issn.1006-2238.2018.1.012.
[2]LINDBLOM R,HIGGINS G,COUGHLAN M,et al.Targeting mitochondria and reactive oxygen species-driven pathogenesis in diabetic nephropathy[J].Rev Diabet Stud,2015,12(1/2):134-156.DOI:10.1900/RDS.2015.12.134.
[3]KARALLIEDDE J,GNUDI L.Diabetes mellitus,a complex and heterogeneous disease,and the role of insulin resistance as a determinant of diabetic kidney disease[J].Nephrol Dial Transplant,2016,31(2):206-213.DOI:10.1093/ndt/gfu405.
[4]邬明辉,杨晓丽,韩秋霞,等.糖尿病肾病研究进展[J].中华肾病研究电子杂志,2018,7(2):86-90.DOI:10.3877/cma.j.issn.2095-3216.2018.02.008.
[5]SHI JX,WANG QJ,LI H,et al.SIRT4 overexpression protects against diabetic nephropathy by inhibiting podocyte apoptosis[J].Exp Ther Med,2017,13(1):342-348.DOI:10.3892/etm.2016.3938.
[6]HUYNH FK,HUX,LIN Z,et al.Loss of sirtuin 4 leads to elevated glucose-and leucine-stimulated insulin levels and accelerated age-induced insulin resistance in multiple murine genetic backgrounds[J].J Inherit Metab Dis,2018,41(1):59-72.DOI:10.1007/s10545-017-0069-8.
[7]STANLEY CA.Regulation of glutamate metabolism and insulin secretion by glutamate dehydrogenase in hypoglycemic children[J].Am J Clin Nutr,2009,90(3):862S-866S.DOI:10.3945/ajcn.2009.27462AA.
[8]AHUJA N,SCHWER B,CAROBBIO S,et al.Regulation of insulin secretion by SIRT4,a mitochondrial ADP-ribosyltransferase[J].J Biol Chem,2007,282(46):33583-33592.
[9]HAIGIS MC,MOSTOSLAVSKY R,HAIGIS KM,et al.SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells[J].Cell,2006,126(5):941-954.DOI:10.1016/j.cell.2006.06.057.
[10]LIU H,LIU R,XIONG Y,et al.Leucine facilitates the insulin-stimulated glucose uptake and insulin signaling in skeletal muscle cells:involving mTORC1 and mTORC2[J].Amino Acids,2014,46(8):1971-1979.DOI:10.1007/s00726-014-1752-9.
[11]ANDESON KA,HUYNH FK,FISHEI-WELLMAN K,et al.SIRT4is a lysine deacylase that controls leucine metabolism and insulin secretion[J].Cell Metab,2017,25(4):838-855.DOI:10.1016/j.cmet.2017.03.003.
[12]ZAGANJOR E,VYAS S,HAIGIS MC.SIRT4 is a regulator of insulin secretion[J].Cell Chem Biol,2017,24(6):656-658.DOI:10.1016/j.chembiol.2017.06.002.
[13]CHEN C,MATALE,FINN RD,et al.Representative proteomes:a stable,scalable and unbiased proteome set for sequence analysis and functional annotation[J].PLoS One,2011,6(4):e18910.DOI:10.1371/journal.pone.0018910.
[14]CHOUBEY SK,PRABHU D,MACHAIPPAN M,et al.Molecular modeling,dynamics studies and density functional theory approaches to identify potential inhibitors of SIRT4 protein from Homo sapiens:a novel target for the treatment of type 2 diabetes[J].J Biomol Struct Dyn,2017,35(15):3316-3329.DOI:10.1080/07391102.2016.1254117.
[15]LAURENT G,GERMAN NJ,SAHA AK,et al.SIRT4 coordinates the balance between lipid synthesis and catabolism by repressing malonyl CoA decarboxylase[J].Mol Cell,2013,50(5):686-698.DOI:10.1016/j.molcel.2013.05.012.
[16]LAURENT G,DE BOER VC,FINLY LW,et al.SIRT4 represses peroxisome proliferator-activated receptorαactivity to suppress hepatic fat oxidation[J].Mol Cell Biol,2013,33(22):4552-4561.DOI:10.1128/MCB.00087-13.
[17]LUO YX,TANG X,AN XZ,et al.SIRT4 accelerates AngⅡ-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity[J].Eur Heart J,2017,38(18):1389-1398.DOI:10.1093/eurheartj/ehw138.
[18]LANG A,ANAND R,ALTINOLUK-HANBUCHEN S,et al.SIRT4interacts with OPA1 and regulates mitochondrial quality control and mitophagy[J].Aging(Albany NY),2017,9(10):2163-2189.DOI:10.18632/aging.101307.
[19]TAO Y,HUANG C,HUANG Y,et al.SIRT4 suppresses inflammatory responses in human umbilical vein endothelial cells[J].Cardiovasc Toxicol,2015,5(3):217-223.DOI:10.1007/s12012-014-9287-6.
[20]TAO J,ZHANG J,LING Y,et al.Mitochondrial sirtuin 4 resolves immune tolerance in monocytes by rebalancing glycolysis and glucose oxidation homeostasis[J].Front Immunol,2018,9:419.DOI:10.3389/fimmu.2018.00419.
[21]KUME S,KOYA D,UZU T,et al.Role of nutrient-sensing signals in the pathogenesis of diabetic nephropathy[J].Biomed Res Int,2014,2014:315494.DOI:10.1155/2014/315494.
[22]吴贤,杨瑜.血清SIRT4水平与肥胖程度及血清IGF-1的相关性研究[J].江西医药,2018,53(1):38-40.DOI:10.3969/j.issn.1006-2238.2018.1.012.